{"organizations": [], "uuid": "59e3352707a69fe0cacd707289c26b443542b813", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-radius-health-provides-update-on-c/brief-radius-health-provides-update-on-chmp-opinion-for-abaloparatide-sc-idUSASC09TCQ", "country": "US", "domain_rank": 408, "title": "BRIEF-Radius Health Provides Update On CHMP Opinion For Abaloparatide-SC", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-22T15:29:00.000+02:00", "replies_count": 0, "uuid": "59e3352707a69fe0cacd707289c26b443542b813"}, "author": "", "url": "https://www.reuters.com/article/brief-radius-health-provides-update-on-c/brief-radius-health-provides-update-on-chmp-opinion-for-abaloparatide-sc-idUSASC09TCQ", "ord_in_thread": 0, "title": "BRIEF-Radius Health Provides Update On CHMP Opinion For Abaloparatide-SC", "locations": [], "entities": {"persons": [{"name": "aba", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 22, 2018 / 1:29 PM / in 17 minutes BRIEF-Radius Health Provides Update On CHMP Opinion For Abaloparatide-SC Reuters Staff March 22 (Reuters) - Radius Health Inc: * RADIUS HEALTH PROVIDES UPDATE ON CHMP OPINION FOR ABALOPARATIDE-SC * RADIUS HEALTH INC - EMA INFORMED CO THAT CHMP WILL ADOPT A NEGATIVE OPINION ON MAA ON THURSDAY * RADIUS HEALTH - INTENDS TO APPEAL AND IMMEDIATELY SEEK A RE-EXAMINATION OF CHMP OPINION * RADIUS HEALTH INC - ‍CHMP COMMUNICATED A NEGATIVE TREND VOTE ON BENEFIT-RISK BALANCE FOR CO’S MARKETING AUTHORIZATION APPLICATION FOR ABALOPARATIDE-SC​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-22T15:29:00.000+02:00", "crawled": "2018-03-22T15:57:20.002+02:00", "highlightTitle": ""}